Tran N. H. Nguyen

Tran N. H. Nguyen

Auto-generated profile, based on publicly available information

Tran N. H. Nguyen

Department of Bioengineering, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2019 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
TNTran N.H. Nguyen
Tran N.H. Nguyen
JNJames K. Nolan
James K. Nolan
HPHyunsu Park
Hyunsu Park
SLStephanie Lam
Stephanie Lam
MFMara Fattah
Mara Fattah
HLHugh Lee
Hugh Lee

27 July 2020 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
TNTran N. H. Nguyen
Tran N. H. Nguyen
XJXin Jin
Xin Jin
JNJames K. Nolan
James K. Nolan
JXJian Xu
Jian Xu
KLKhanh Vy H. Le
Khanh Vy H. Le
HLHugh Lee
Hugh Lee

6 September 2024 in Science Advances
Verified
Journal Article
Open access
TNTran N. H. Nguyen
Tran N. H. Nguyen
LHLisa F. Horowitz
Lisa F. Horowitz
TKTimothy Krilov
Timothy Krilov
ELEthan Lockhart
Ethan Lockhart
HKHeidi L. Kenerson
Heidi L. Kenerson
Albert FolchAlbert Folch
Albert Folch
Functional assays on intact tumor biopsies can complement genomics-based approaches for precision oncology, drug testing, and organs-on-chips cancer disease models by capturing key therapeutic response determinants, such as tissue architecture, tumor heterogeneity, and the tumor microenvironment. Most of these assays rely on fluorescent labeling, a semiquantitative method best suited for single-time-point assays or labor-intensive immunostaining analysis. Here, we report integrated aptamer electrochemical sensors for on-chip, real-time monitoring of cytochrome C, a cell death indicator, from intact microdissected tissues with high affinity and specificity. The platform features a multi-well sensor layout and a multiplexed electronic setup. The aptasensors measure increases in cytochrome C in the supernatant of mouse or human microdissected tumors after exposure to various drug treatments. Because of the sensor’s high affinity, it primarily tracks rising concentrations of cytochrome C, capturing dynamic changes during apoptosis. This approach could help develop more advanced cancer disease models and apply to other complex in vitro disease models, such as organs-on-chips and organoids.

16 May 2025 in Science Advances
Verified
Journal Article
Open access
ISIvan Stepanov
Ivan Stepanov
NGNoah R. Gottshall
Noah R. Gottshall
AAAlireza Ahmadianyazdi
Alireza Ahmadianyazdi
DSDaksh Sinha
Daksh Sinha
ELEthan J. Lockhart
Ethan J. Lockhart
Albert FolchAlbert Folch
Albert Folch
The scarcity of human biopsies available for drug testing is a paramount challenge for developing therapeutics, disease models, and personalized treatments. Microtechnologies that combine the microscale manipulation of tissues and fluids offer the exciting possibility of miniaturizing both disease models and drug testing workflows on scarce human biopsies. Unfortunately, these technologies presently require microfluidic devices or robotic dispensers that are not widely accessible. We have rapidly prototyped an inexpensive platform based on an off-the-shelf robot that can microfluidically manipulate live microtissues into/out of culture plates without using complicated accessories such as microscopes or pneumatic controllers. The robot integrates complex functions with a simple, cost-effective, and compact construction, allowing placement inside a tissue culture hood for sterile workflows. We demonstrated a proof-of-concept cancer drug evaluation workflow of potential clinical utility using patient tumor biopsies with multiple drugs on 384-well plates. Our user-friendly, low-cost platform promises to make drug testing of microtissues broadly accessible to pharmaceutical, clinical, and biological laboratories.

29 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
TNTran N. H. Nguyen
Tran N. H. Nguyen
LHLisa F. Horowitz
Lisa F. Horowitz
BNBrandon Nguyen
Brandon Nguyen
ELEthan Lockhart
Ethan Lockhart
SZSongli Zhu
Songli Zhu
AFAlbert Folch
Albert Folch
The microvasculature within the tumor microenvironment (TME) plays an essential role in cancer signaling beyond nutrient delivery. However, it has been challenging to control the generation and/or maintenance of microvasculature in ex vivo systems, a critical step for establishing cancer models of high clinical biomimicry. There have been great successes in engineering tissues incorporating microvasculature de novo ( e.g. , organoids and organs-on-chip), but these reconstituted tissues are formed with non-native cellular and molecular components that can skew certain outcomes such as drug efficacy. Microdissected tumors, on the other hand, show promise in preserving the TME, which is key for creating cancer models that can bridge the gap between bench and bedside. However, microdissected tumors are challenging to perfuse. Here, we developed a microfluidic platform that allows for perfusing the microvasculature of microdissected tumors. We demonstrate that, compared to diffusive transport, microfluidically perfused tissues feature larger and longer microvascular structures, with a better expression of CD31, a marker for endothelial cells, as analyzed by 3D imaging. This study also explores the effects of nitric oxide pathway-related drugs on endothelial cells, which are sensitive to shear stress and can activate endothelial nitric oxide synthase, producing nitric oxide. Our findings highlight the critical role of controlled perfusion and biochemical modulation in preserving tumor microvasculature, offering valuable insights for developing more effective cancer treatments.